



Magnum Compounding LLC  
490 W 84 St, Hialeah, FL 33014  
Phone: (786) 622-2301  
Fax: (786) 622-2319  
Toll Free: (855) 403-6028

**LET'S DO THIS  
TOGETHER**

## COMPOUNDED INJECTABLE FORMULA INFORMATION SHEET

**Product Name:** NAD+ Injection (Nicotinamide Adenine Dinucleotide)

**Formulation Type:** Sterile Injectable Solution (Intramuscular Use/ Intravenous Use/ Subcutaneous Use)

**Vial Size:** 5 mL Multi-Dose Vial (MDV)

**Concentration:** 200 mg / mL

### ACTIVE INGREDIENTS (per mL)

Ingredients	Strength (mg / mL)	Role & Benefits
NAD+ ( $\beta$ -Nicotinamide Adenine Dinucleotide)	200 (1000 mg per 5 mL vial)	Cellular metabolism and mitochondrial energy production in functional and integrative medicine protocols to support energy metabolism, cognitive performance, and cellular repair.

### OTHER INGREDIENTS:

- Benzyl Alcohol 0.9% (Preservative)
- Water for Injection, USP (Vehicle)
- pH adjusted with Sodium Hydroxide and/or Hydrochloric Acid

**DESCRIPTION:** NAD<sup>+</sup> (Nicotinamide Adenine Dinucleotide) Injection is a sterile compounded solution intended for intramuscular administration as prescribed by a licensed healthcare provider. NAD<sup>+</sup> is an essential intracellular coenzyme involved in cellular energy production, mitochondrial function, and DNA repair mechanisms.

**INDICATIONS:** NAD<sup>+</sup> (Nicotinamide Adenine Dinucleotide) is an endogenous coenzyme essential for cellular metabolism and energy production. Compounded NAD<sup>+</sup> injection is dispensed only pursuant to a valid prescription and may be used as part of medically supervised protocols in functional and integrative medicine, including:

- Support of cellular energy production (ATP)
- Support of mitochondrial function
- Metabolic and wellness support
- Support in fatigue and cellular recovery
- Healthy aging protocols, at the discretion of the prescriber

**If you have any questions or concerns regarding your medication, please do not hesitate to contact us.**



Magnum Compounding LLC  
490 W 84 St, Hialeah, FL 33014  
Phone: (786) 622-2301  
Fax: (786) 622-2319  
Toll Free: (855) 403-6028

**LET'S DO THIS  
TOGETHER**

**DOSAGE & ADMINISTRATION:** Dosage and frequency are determined by the prescriber based on individual patient needs and therapeutic goals. Intravenous administration of NAD<sup>+</sup> requires slow and controlled infusion by trained medical personnel. Infusion rate is a critical safety factor. The pharmacy does NOT administer this medication and does NOT control infusion rate or technique. This product is to be dispensed and administered only under licensed medical supervision.

**STORAGE:** Refrigerate at 2°C to 8°C (36°F to 46°F). Protect from light. Do not freeze. Use only if the solution is clear and free of particulate matter.

**WARNINGS & PRECAUTIONS:** Inform the prescriber of all medical conditions, allergies, and concurrent medications before use. Possible transient effects may include warmth, flushing, chest pressure, headache, or fatigue. Seek medical attention for allergic reactions, chest pain, shortness of breath, or severe weakness. **Discontinue administration immediately if severe symptoms occur and seek medical evaluation.** Improper or rapid intravenous administration of NAD<sup>+</sup> may result in serious adverse reactions, including but not limited to severe nausea, chest tightness or pressure, shortness of breath, intense anxiety, tachycardia, transient hypertension, muscle spasms, seizures, and acute neurologic symptoms. The risk of severe reactions increases significantly when NAD<sup>+</sup> is infused too rapidly.

For patient safety:

- NAD<sup>+</sup> IV must be appropriately diluted
- Must be administered as a slow infusion, commonly over 3–4 hours, per prescriber protocol
- Must be administered in a medically supervised clinical setting

**CONTRAINDICATIONS:**

- Known hypersensitivity to NAD<sup>+</sup>
- Pregnancy or breastfeeding (use only if the benefit outweighs risk)
- Use caution in patients with advanced renal disease, severe hepatic impairment, uncontrolled asthma, or active neurologic disorders.

**INJECTION SAFETY CONSIDERATIONS (CDC GUIDANCE):**

- Medications should be drawn up in a designated clean medication preparation area using a new sterile syringe and sterile needle.
- Prepare an injection as close as possible to the time of administration to the patient.
- Do NOT leave the needle inserted into a medication vial septum for multiple uses.

**If you have any questions or concerns regarding your medication, please do not hesitate to contact us.**



Magnum Compounding LLC  
490 W 84 St, Hialeah, FL 33014  
Phone: (786) 622-2301  
Fax: (786) 622-2319  
Toll Free: (855) 403-6028

**LET'S DO THIS  
TOGETHER**

- Vials labeled as single-dose or single-use should be used for only a single patient and entered only once.
- Do NOT combine (pool) leftover contents of single-dose or single-use vials or store them for later use.
- If a single-dose or single-use vial has been opened or accessed (e.g., needle-punctured), it should be discarded according to pharmacy policy or at the end of the procedure, whichever is sooner.
- Discard any medication vial if sterility is compromised or questionable.
- Multi-dose vials should be dedicated to a single patient whenever possible.
- Once opened, multi-dose vials must be dated and discarded within 28 days unless otherwise specified by the pharmacy label.

#### **LEGAL DISCLAIMER:**

Magnum Compounding LLC compounds and dispenses this preparation solely pursuant to a valid prescription.

- The pharmacy does not prescribe
- The pharmacy does not administer
- The pharmacy does not supervise the infusion technique or infusion rate

The following are the sole responsibility of the prescriber and administering healthcare professional:

- Dose selection
- Route of administration
- Infusion rate and dilution
- Patient monitoring and clinical assessment

#### **REFERENCE:**

1. Ying W. *NAD<sup>+</sup> and NADH in cellular functions and cell death*. *Frontiers in Bioscience*. 2006;11:3129–3148.
2. Verdin E. *NAD<sup>+</sup> in aging, metabolism, and neurodegeneration*. *Science*. 2015;350(6265):1208–1213.
3. Rajman L, Chwalek K, Sinclair DA. *Therapeutic potential of NAD<sup>+</sup>-boosting molecules*. *Cell Metabolism*. 2018;27(3):529–547.
4. Katsyuba E, Auwerx J. *Modulating NAD<sup>+</sup> metabolism, from bench to bedside*. *EMBO Journal*. 2017;36(18):2670–2683.
5. ASPEN Clinical Guidelines – Parenteral Therapy Safety *Safe administration practices for intravenous therapies*.

**If you have any questions or concerns regarding your medication, please do not hesitate to contact us.**